Antigen expression
| Patient ID . | None . | Labetuzumab (CEA, isotype control) . | IMMU-114 (HLA-DR) . | Milatuzumab (CD74) . | Epratuzumab (CD22) . | Veltuzumab (CD20) . |
|---|---|---|---|---|---|---|
| CLL030 | 4.5 | 4.5 | 23.2 | 6.8 | 5.3 | 20.1 |
| CLL037 | 4.6 | 5.6 | 505.8 | 15.5 | 10.1 | 87.2 |
| CLL078 | 4.8 | 7.0 | 919.0 | 30.9 | 7.7 | 284.3 |
| CLL107 | 15.6 | 10.9 | 148.6 | 11.9 | 12.5 | 85.0 |
| CLL113 | 15.4 | 23.0 | 728.6 | 59.9 | 26.2 | 411.3 |
| CLL117 | 21.6 | 23.4 | 90.9 | 30.2 | 25.2 | 111.0 |
| Patient ID . | None . | Labetuzumab (CEA, isotype control) . | IMMU-114 (HLA-DR) . | Milatuzumab (CD74) . | Epratuzumab (CD22) . | Veltuzumab (CD20) . |
|---|---|---|---|---|---|---|
| CLL030 | 4.5 | 4.5 | 23.2 | 6.8 | 5.3 | 20.1 |
| CLL037 | 4.6 | 5.6 | 505.8 | 15.5 | 10.1 | 87.2 |
| CLL078 | 4.8 | 7.0 | 919.0 | 30.9 | 7.7 | 284.3 |
| CLL107 | 15.6 | 10.9 | 148.6 | 11.9 | 12.5 | 85.0 |
| CLL113 | 15.4 | 23.0 | 728.6 | 59.9 | 26.2 | 411.3 |
| CLL117 | 21.6 | 23.4 | 90.9 | 30.2 | 25.2 | 111.0 |
Values are mean fluorescence intensities.